Don't want ads? Subscribe or login now.

Biotech Firm Omega Therapeutics OK'd For $14M Ch. 11 Sale

By Clara Geoghegan · April 23, 2025, 5:18 PM EDT

Biotechnology developer Omega Therapeutics received a Delaware bankruptcy judge's approval Wednesday to sell itself to its debtor-in-possession lender and a major shareholder for $14 million in Chapter 11....

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Bankruptcy Scorecard

Summary

Biotechnology company Omega Therapeutics hit Chapter 11 in Delaware, listing over $140 million of debt on its petition and having filed a form with the U.S. Securities and Exchange Commission saying it had entered a restructuring agreement with an affiliate of its controlling stockholder.

Case Number

1:25-bk-10211

Judge

Brendan L. Shannon

Venue

U.S. Bankruptcy Court for the Northern District of Alabama

Capital Structure

Total Liabilities:

Over $140.4 million in debt

View Full Scorecard